

Progress toward the Total Synthesis of Pleurotin

SHINYA IIMURA




Wipf Research Group Meeting
July 9th, 2005



Presentation Outline

- Isolation and Structure
- Biological Activity
- Hart's Total Synthesis (Racemic)
- Kraus' Studies toward Total Synthesis
- Previous Studies in the Wipf Group
- Current Total Synthesis Efforts in the Wipf Group
- Future Plans

Isolation and Properties of Pleurotin



- First isolated from the fungus *Pleurotus griseus* in 1947 by Robbins *et al.*, and later obtained from *Hohenbuehelia geogenius*.
- Pleurotin began to melt with decomposition at temperatures between 200 °C and 215 °C depending upon the rate of heating.
- Pleurotin was optically active with $[\alpha]^{23}_D = -20^\circ$ (*c* 0.59, CHCl₃).
- The solubility of pleurotin at 25 °C: 0.125 mg/mL (water), 6.8 mg/mL (95% ethanol), 0.37 mg/mL (5% ethanol), 3.5 mg/mL (ether), more than 200 mg/mL (chloroform).
- Pleurotin was not thermostable. Solutions of pleurotin in 0.1 M. phosphate buffer when boiled for 10 min lost 50% of their biological activity at pH 3, 75% at pH 6.5, and all of their activity at pH 8.5.
- Pleurotin was 75% destroyed in 1 h at pH 8.5 and 25 °C.
- Pleurotin in solution was rendered inactive by exposure to light for a few hours.

Robbins, W. J. *et al. Proc. Natl. Acad. Sci. USA*, **1947**, 33, 171.

Structure and the Synthetic Challenges





Fig. 3. Conformation de la géogenine dans la structure $P_{2}2_{1}2_{1}$ (cristallisation dans le méthanol). Plan de projection: C(1)-C(2)-C(6).


- Structure originally assigned on the basis of degradative studies in 1968 and later confirmed by X-ray crystallography in 1981.

Oddoux, L. et al. *Arzneim. Forsch.* **1981**, 31, 293.

Cohen-Addad, P. C. et al. *Acta Crystallogr.* **1981**, B37, 1309.

- The Challenge to Synthetic Chemists: The unique compact hexacyclic framework
The six contiguous stereogenic centers
No enantioselective total synthesis

Biological Activity



- Antibiotic activity against Gram-positive bacteria.

Robbins, W. J. *et al. Proc. Natl. Acad. Sci. USA*, **1947**, *33*, 171.

- Antitumor activity against two rapidly grafted tumors: Ehrlich ascites carcinoma and L-1210 lymphoid leukemia, as well as a slow growing spontaneous mammary tumor.

Oddoux, L. *et al. Arzneim. Forsch.* **1981**, *31*, 293.

- A potent inhibitor of the thioredoxin–thioredoxin reductase system (IC₅₀ 170 nM).

Powis, G. *et al. Anti-Cancer Drug Des.*, **1997**, *12*, 659.

Powis, G. *et al. Mol. Cancer Ther.*, **2003**, *2*, 235.

Wipf, P. *et al. Org. Biomol. Chem.*, **2004**, *2*, 1651.

Bioreductive Alkylation


“ The concept of bioactivation as a mechanism of drug action is one that is especially appealing to the medicinal and synthetic organic chemist. The challenge of designing compounds in a biologically inactive form which become activated only subsequent to an *in vivo* transformation allows the synthesis chemist to take advantage of his arsenal of methodology and mechanistic probes and to directly apply them to potentially important problems of drug action. ”

Moore, H. W. *Science (Washington, D.C.)* **1977**, 197, 527.


The concept of bioreductive alkylation which is compounds which become potent alkylating agents after they undergo a reduction *in vivo*, is a particularly fascinating area within the field of bioactivation.

Lin. A. J. et al., *J. Med. Chem.* **1972**, 15, 1247.
Moore, H. W. *Science (Washington, D.C.)* **1977**, 197, 527.

Bioreductive Alkylation




Suggested Bioactivation of Pleuotin



Moore, H. W. *Science (Washington, D.C.)* **1977**, *197*, 527.
Hart, D. J. et al. *J. Am. Chem. Soc.* **1989**, *111*, 7507.


Hart: First Total Synthesis of Pleurotin (Racemic)



*Arigoni group has demonstrated that dihydropleurotin acid is converted to pleurotin by cultures of *Pleurotus griseus*. Vogt, P.M. Ph. D. Thesis, Eidgenössischen Technischen Hochschule, Zurich, Switzerland, 1982.


Hart, D. J. et al. *J. Am. Chem. Soc.* **1988**, *110*, 1634.
Hart, D. J. et al. *J. Am. Chem. Soc.* **1989**, *111*, 7507.

Hart: First Total Synthesis of Pleurotin (Racemic)




Hart, D. J. et al. *J. Am. Chem. Soc.* **1988**, *110*, 1634.
 Hart, D. J. et al. *J. Am. Chem. Soc.* **1989**, *111*, 7507.

Hart: Stereoselectivity in the Free-Radical Cyclization




Hart: First Total Synthesis of Pleurotin (Racemic)



Hart, D. J. et al. *J. Am. Chem. Soc.* **1988**, *110*, 1634.
 Hart, D. J. et al. *J. Am. Chem. Soc.* **1989**, *111*, 7507.

Hart: First Total Synthesis of Pleurotin (Racemic)




26 steps from benzoic acid
0.3% overall yield
an average of 80% yield per step

Hart, D. J. et al. *J. Am. Chem. Soc.* 1988, 110, 1634.
Hart, D. J. et al. *J. Am. Chem. Soc.* 1989, 111, 7507.



Kraus: Retrosynthetic Analysis of Pleurotin

Tandem Photoenolization/Diels–Alder Reaction



Kraus, G. A. et al. *Synlett* **1991**, 89.
Kraus, G. A. et al. *Synth. Commun.* **1993**, 23, 2041.

Kraus: Synthetic Studies toward Pleurotin



Kraus, G. A. et al. *Synlett* **1991**, 89.

Kraus, G. A. et al. *Synth. Commun.* **1993**, 23, 2041.

Acknowledgments

**Prof. Dr. Peter Wipf
Dr. Sonia Rodríguez
Dr. Steven Geib (X-ray)**

Wipf research group members
University of Pittsburgh
\$ National Institutes of Health (GM66509) \$